Sihuan Pharmaceutical Holdings Group (HKSE:00460) Long-Term Capital Lease Obligation : HK$33 Mil (As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

What is Sihuan Pharmaceutical Holdings Group Long-Term Capital Lease Obligation?

Sihuan Pharmaceutical Holdings Group's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$33 Mil.

Sihuan Pharmaceutical Holdings Group's quarterly Long-Term Capital Lease Obligation declined from Dec. 2022 (HK$51 Mil) to Jun. 2023 (HK$40 Mil) and declined from Jun. 2023 (HK$40 Mil) to Dec. 2023 (HK$33 Mil).

Sihuan Pharmaceutical Holdings Group's annual Long-Term Capital Lease Obligation increased from Dec. 2021 (HK$39 Mil) to Dec. 2022 (HK$51 Mil) but then declined from Dec. 2022 (HK$51 Mil) to Dec. 2023 (HK$33 Mil).

Sihuan Pharmaceutical Holdings Group Long-Term Capital Lease Obligation Historical Data

The historical data trend for Sihuan Pharmaceutical Holdings Group's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sihuan Pharmaceutical Holdings Group Long-Term Capital Lease Obligation Chart

Sihuan Pharmaceutical Holdings Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

6.56

2.98

38.53

51.21

33.12

Sihuan Pharmaceutical Holdings Group Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															38.53	55.24	51.21	40.08	33.12

Sihuan Pharmaceutical Holdings Group (HKSE:00460) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Sihuan Pharmaceutical Holdings Group Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Sihuan Pharmaceutical Holdings Group's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Sihuan Pharmaceutical Holdings Group (HKSE:00460) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sihuan Pharmaceutical Holdings Group Ltd (HKSE:00460) » Definitions » Long-Term Capital Lease Obligation

Traded in Other Exchanges

SHPHF:USA

Address

Zhubang 2000 Business Centre, 22nd Floor, Building 4, West Balizhuang, Chaoyang District, Beijing, CHN, 100025

Website

https://www.sihuanpharm.com

Sihuan Pharmaceutical Holdings Group Ltd is an investment holding company. Along with its subsidiaries, the company is engaged in the research & development and the manufacture & sale of pharmaceutical products. Its portfolio comprises products for diseases related to the cardio-cerebral vascular (CCV) system, Digestive System, Anti-Infective, metabolism, Respiratory, Neurology, and Others. The group has three reportable segments: the medical aesthetic products segment including the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skincare, and others to provide non- or minimally invasive medical aesthetics comprehensive solutions; the innovative medicine and other medicine segments; and the generic medicine segment.

Executives

Che Fengsheng	2201 Interest of corporation controlled by you
Guo Weicheng	2201 Interest of corporation controlled by you
Meng Xianhui	2201 Interest of corporation controlled by you
Zhang Jionglong	2201 Interest of corporation controlled by you
Mingyao Capital Limited	2401 A concert party to an agreement to buy shares
Network Victory Limited	2401 A concert party to an agreement to buy shares
Proper Process International Limited	2401 A concert party to an agreement to buy shares
Successmax Global Holdings Limited	2101 Beneficial owner
Victory Faith International Limited	2401 A concert party to an agreement to buy shares
Ubs Tc (jersey) Ltd	2301 Trustee
Ubs Trustees (cayman) Ltd.	2301 Trustee
Smart Top Overseas Limited	2501 Other
Plenty Gold Enterprises Limited	2307 Founder of a discretionary trust who can infl

Sihuan Pharmaceutical Holdings Group (HKSE:00460) Headlines

No Headlines